SHS Capital acquires majority stake in Medizintechnik Rostock (MTR)

Tübin­gen — SHS Capi­tal has acqui­red a majo­rity stake in the German medi­cal tech­no­logy company Medi­zin­tech­nik Rostock (MTR) with its sixth fund gene­ra­tion (SHS VI). The aim of the invest­ment is to further grow the core busi­ness and to support the nati­on­wide expan­sion that has alre­ady been initia­ted. One and a half years after final closing, SHS VI has thus inves­ted over 50% of the fund’s investa­ble capi­tal. The medium-sized company Medi­zin­tech­nik Rostock GmbH was foun­ded in 1994, employs around 200 people and focu­ses on the provi­sion of therapy devices for home use. As a quality leader in Germany, MTR is a part­ner of over 80 health insu­rance compa­nies and carried out over 140,000 treat­ments in the areas of move­ment, elec­tri­cal and compres­sion therapy in 2023. Of the three appli­ca­tion areas in which MTR is active, move­ment therapy is the largest area. The conti­nuous passive motion (CPM) devices are used to help pati­ents restore joint mobi­lity after opera­ti­ons such as knee and hip repla­ce­ments or shoulder and elbow surgery. Another area is elec­tro­the­rapy. Here, elec­tri­cal impul­ses are used to stimu­late muscles, reli­eve pain or treat neuro­lo­gi­cal disor­ders. The newest area is compres­sion therapy. The focus here is on the treat­ment of lymph­oedema and venous disor­ders. Using inter­mit­tent pneu­ma­tic compres­sion (IPC) devices, sequen­tial pres­sure is applied to the affec­ted areas to improve circu­la­tion and reduce swel­ling. If a doctor prescri­bes therapy with an MTR therapy device for a pati­ent as part of the reco­very process, the costs are usually covered by health insu­rance. The therapy devices are then deli­vered to pati­ents for the requi­red reha­bi­li­ta­tion phase as part of a rental busi­ness model. The company also has the neces­sary service and trai­ning staff to make it easier for pati­ents to start therapy and use the devices or to cali­brate the device precis­ely to the indi­vi­dual requi­re­ments of each pati­ent. This service is carried out by MTR’s own staff and thus guaran­tees not only consis­t­ently high quality and pati­ent care, but also fast and indi­vi­dual deli­veries to the respec­tive pati­ents. Thanks to this high quality of service, MTR enjoys an excel­lent repu­ta­tion among prescrib­ing doctors and has been able to conti­nuously increase its supply figu­res in recent years. “Toge­ther with SHS, MTR will realize an important step on its expan­sion and growth path. We look forward to the support of SHS through their sector exper­tise and network in the health­care sector and hope to be able to successfully support even more pati­ents throug­hout Germany in their health reco­very proces­ses through close coope­ra­tion with SHS,” explains MTR share­hol­der Andreas Mark­schies. “I am very plea­sed that we have found the right part­ner for our company, who under­stands and respects our company history and will support us in achie­ving our further goals,” says MTR share­hol­der Matthias Liewehr. 

“We are deligh­ted to have the oppor­tu­nity to support the contin­ued growth of MTR. Since its foun­da­tion 30 years ago, the focus has always been on opti­mal pati­ent care, which has estab­lished MTR as a quality leader in its therapy segments. We want to conti­nue this success story toge­ther with the manage­ment and thus give even more pati­ents access to these therapy opti­ons. We will bene­fit from our exper­tise and expe­ri­ence in the home­care sector, which we have alre­ady demons­tra­ted in other invest­ments, such as our previous invest­ment in Medi­groba GmbH,” says SHS Capi­tal Senior Invest­ment Mana­ger Tobias Fuchs. About Medi­zin­tech­nik Rostock GmbH (MTR)

Foun­ded in 1994, Medi­zin­tech­nik Rostock GmbH is a medium-sized company for pati­ent care with medi­cal products, medi­cal tech­no­logy and medi­cal aids in the fields of move­ment, elec­tro and compres­sion therapy. The company employs a total of around 200 people at its main sites in Rostock and Berlin as well as in its nati­on­wide sales force. The focus of its acti­vi­ties is the provi­sion of medi­cal aids in the home envi­ron­ment. For many years, MTR has been a contrac­tual part­ner of almost all statu­tory health insu­rance funds, employ­ers’ liabi­lity insu­rance asso­cia­ti­ons and other service provi­ders. https://mtronline.de/ About SHS Gesell­schaft für Betei­li­gungs­ma­nage­ment mbH

SHS is a private equity inves­tor foun­ded in 1993 that makes invest­ments in health­care compa­nies in Europe.

The focus of invest­ments is on expan­sion finan­cing, share­hol­der chan­ges and succes­sion situa­tions. “Buil­ding Euro­pean Health­care Cham­pi­ons” is the invest­ment philo­so­phy accor­ding to which SHS finan­ces and deve­lops port­fo­lio compa­nies. The Tübin­­gen-based inves­tor is taking both mino­rity and majo­rity stakes. SHS funds’ natio­nal and inter­na­tio­nal inves­tors include pension funds, funds of funds, foun­da­ti­ons, family offices, stra­te­gic inves­tors, entre­pre­neurs and the SHS manage­ment team. The equity or equity-like invest­ment of the AIF amounts to up to € 50 million. Volu­mes in excess of this can be reali­zed with a network of co-inves­­tors. In its invest­ment decis­i­ons, SHS places strong empha­sis on the conside­ra­tion of ESG aspects and has ther­e­fore commit­ted itself to the guide­lines of the UN PRI. SHS is curr­ently inves­t­ing from its sixth fund, which was laun­ched in 2022 and has a volume of around € 270 million. http://www.shs-capital.eu